Valuation: Bellicum Pharmaceuticals, Inc.

Market Cap 1.76M 1.54M 1.45M 1.32M 2.47M 169M 2.48M 17.34M 6.7M 86.07M 6.63M 6.48M 277M P/E 2021
-1.77x
P/E 2022 -0.89x
Enterprise Value -20.07M -17.49M -16.51M -14.99M -28.09M -1.92B -28.19M -197M -76.22M -979M -75.4M -73.72M -3.15B EV / Sales 2021
-5.43x
EV / Sales 2022 -10.4x
Free-Float
98.45%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 66 2024-02-22
Chief Executive Officer 57 2017-01-30
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-6.68%-18.17% - - 822K
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+0.50%+7.13%+33.27%+20.02% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+329.34% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average -0.86%+1.74%+36.57%+211.44% 30.54B
Weighted average by Cap. -0.28%+1.49%+35.68%+150.57%

Financials

2021 2022
Net sales 6.2M 5.4M 5.1M 4.63M 8.68M 594M 8.71M 60.92M 23.54M 302M 23.29M 22.77M 974M 1.5M 1.31M 1.23M 1.12M 2.1M 144M 2.11M 14.74M 5.7M 73.16M 5.63M 5.51M 236M
Net income -9.7M -8.45M -7.98M -7.25M -13.58M -930M -13.63M -95.36M -36.85M -473M -36.45M -35.64M -1.52B -24.97M -21.76M -20.54M -18.65M -34.95M -2.39B -35.07M -245M -94.83M -1.22B -93.8M -91.72M -3.92B
Net Debt -46.16M -40.21M -37.96M -34.47M -64.59M -4.42B -64.81M -454M -175M -2.25B -173M -170M -7.25B -21.84M -19.02M -17.96M -16.31M -30.56M -2.09B -30.66M -215M -82.93M -1.07B -82.02M -80.2M -3.43B
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!